Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 1, 2007, Pages 41-49

  Garnier, Tracy ^a,b   Mäntylä, Antti ^c   Järvinen, Tomi ^c   Lawrence, M Jayne ^d   Brown, Marc B ^a,d   Croft, Simon L ^b,e  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e Drugs for Neglected Diseases Initiative   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

3 PHOSPHONO EXYMETHYL BUPARVAQUONE; BUPARVAQUONE; MELANIN; PRODRUG; SITAMAQUINE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG STRUCTURE; EMULSION; GEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOUSE; NONHUMAN; SKIN LEISHMANIASIS;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIPROTOZOAL AGENTS; CHEMISTRY, PHARMACEUTICAL; ETHANOL; FEMALE; HUMANS; LEISHMANIASIS, CUTANEOUS; MELANINS; MICE; MICE, INBRED BALB C; MYRISTATES; NAPHTHOQUINONES; PHOSPHORIC ACID ESTERS; POLYETHYLENE GLYCOLS; PRODRUGS; PROPYLENE GLYCOL; SKIN; SKIN ABSORPTION;

EID: 33846374086     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.1.0006     Document Type: Article

References (41)

1. Arellano, A., Santoyo, S., Martin, C., Ygartua, P. (1999) Influence of propylene glycol and isopropyl myristate on the in vitro percutaneous penetration of diclofenac sodium from carbopol gels. Eur. J. Pharm. Sci. 7: 129-135
2. Arnardottir, H. B., Sveinsson, S. J., Kristmundsdóttir, T. (1996) The release of clindamycin phosphate from a suspension of different types of liposomes and selected topical dosage forms. Int. J. Pharm. 134: 71-77
3. Asilian, A., Jalayer, T., Whitworth, J. A., Ghasemi, R. L., Nilforooshzadeh, M., Olliaro, P. (1995) A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am. J. Trop. Med. Hyg. 53: 648-651
4. Banning, T. P., Heard, C. M. (2002) Binding of doxycycline to keratin, melanin and human epidermal tissue. Int. J. Pharm. 235: 219-227
5. Bashir, S. J., Chew, A. L., Anigbogu, A., Dreher, F., Maibach, H. I. (2001) Physical and physiological effects of stratum corneum tape stripping. Skin Res. Technol. 7: 40-48
6. Beckley-Kartey, S. A., Hotchkiss, S. A., Capel, M. (1997) Comparative in vitro skin absorption and metabolism of coumarin (1,2-benzopyrone) in human, rat, and mouse. Toxicol. Appl. Pharmacol. 145: 34-42
7. Ben Salah, A., Zakraoui, H., Zaatour, A., Ftaiti, A., Zaafouri, B., Garraoui, A., Olliaro, P. L., Dellagi, K., Ben Ismail, R. (1995) A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am. J. Trop. Med. Hyg. 53: 162-166
8. Ben Salah, A., Buffet, P. A., Louzir, H., Morizot, G., Zaatour, A., Ben Alaya, N., Bel Hajhmida, N., Elahmadi, Z., Chlif, S., Lehnert, E., Doughty, S., Dellagi, K., Grogl, M. (2005) WR279396 an efficient non toxic topical treatment of Old World cutaneous leishmaniosis. Proceedings of the WorldLeish III Conference, 10-15 April 2005, Italy
9. Berman, J. D. (2005) Recent developments in leishmaniasis: epidemiology, diagnosis and treatment. Curr. Infect. Dis. Rep. 7: 33-38
10. Couteau, C., Perez Cullel, N., Connan, A. E., Coiffard, L. J. (2001) Stripping method to quantify absorption of two sunscreens in human. Int. J. Pharm. 222: 153-157
11. Croft, S. L., Coombs, G. H. (2003) Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19: 502-508
12. Croft, S. L., Hogg, J., Gutteridge, W. E., Hudson, A. T., Randall, A. W. (1992) The activity of hydroxynaphthoquinones against Leishmania donovani. J. Antimicrob. Chemother. 30: 827-832
13. Desjeux, P. (2004) Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 27: 305-318
14. El-On, J., Jacobs, G. P., Witztum, E., Greenblatt, C. L. (1984) Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. J. Antimicrob. Chemother. 26: 745-751
15. El-On, J., Livshin, R., Even-Paz, Z., Hamburger, D., Weinrauch, L. (1986) Topical treatment of cutaneous leishmaniasis. J. Invest. Dermatol. 87: 284-288
16. Fukuda, M., Morita, Y., Sasaki, K., Yamamoto, Y. (2000) Studies on the binding mechanism of fluoroquinolones to melanin. J. Infect. Chemother. 6: 72-76
17. Garnier, T., Croft, S. L. (2002) Topical treatment for cutaneous leishmaniasis. Curr. Opin. Investig. Drugs 3: 538-544
18. Garnier, T., Brown, M., Lawrence, J., Croft, S. (2006) In vitro and in vivo studies for sitamaquine against cutaneous leishmaniasis. J. Pharm. Pharmacol. 58: 1043-1054
19. Hadgraft, J. (2001) Skin, the final frontier. Int. J. Pharm. 224: 1-18
20. Hadgraft, J., Pugh, W. J. (1998) The selection and design of topical and transdermal agents: a review. J. Investig. Dermatol. Symp. Proc. 3: 131-135
21. Heard, C. M., Monk, B. V., Modley, A. J. (2003) Binding of primaquine to epidermal membranes and keratin. Int. J. Pharm. 257: 237-244
22. Howes, D., Guy, R., Hadgraft, J., Heylings, J., Hoeck, U., Kemper, F., Maibach, H., Marty, J. P., Merk, H., Parra, J., Rekkas, D., Rondelli, I., Schaefer, H., Täuber, U., Verbiese, N. (1996) Methods for assessing percutaneous absorption: the report and recommendations of ECVAM workshop 13. ATLA 24: 81-106
23. Kibbe, A. H. (2000) Handbook of pharmaceutical excipients, 3rd edn. American Pharmaceutical Association, Washington, DC and Pharmaceutical Press, London
24. Kinabo, L. D., Bogan, J. A. (1988) Parvaquone and buparvaquone: HPLC analysis and comparative pharmacokinetics in cattle. Acta Trop. 45: 87-94
25. Kligman, A. M., Christophers, E. (1963) Preparation of isolated sheets of human stratum corneum. Arch. Dermatol. 88: 702-705
26. Larsson, B. S. (1993) Interactions between chemicals and melanin. Pigment Cell Res. 6: 127-133
27. Magnusson, B. M., Walters, K. A., Roberts, M. S. (2001) Veterinary drug delivery: potential for skin penetration enhancement. Adv. Drug Deliv. Rev. 50: 205-227
28. Mäntylä, A., Garnier, T., Rautio, J., Nevalainen, T., Vepsalainen, J., Koskinen, A., Croft, S. L., Jarvinen, T. (2004) Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. J. Med. Chem. 47: 188-195
29. Meyerhoff, A. (1999) U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin. Infect. Dis. 28: 42-51
30. Murray, H. W., Berman, J. D., Davies, C. R., Saravia, N. G. (2005) Advances in leishmaniasis. Lancet 366: 1561-1577
31. Nohynek, G. J., Fautz, R., Benech-Kieffer, F., Toutain, H. (2004) Toxicity and human health risk of hair dyes. Food Chem. Toxicol. 42: 517-543
32. Qureshi, S. A., Jiang, M., Midha, K. K., Skelly, J. P. (1998) In vitro evaluation of percutaneous absorption of an acyclovir product using intact and tape-stripped human skin. J. Pharm. Pharm. Sci. 1: 102-107
33. Séné, C., Neun, D., Tan-Sien-Hee, L., Ulman, K. (2002) Silicones as excipients for topical pharmaceutical applications: the silky touch product family from Dow Corning. (Accessed 12 Mar 2006). Available from: http://www.dowcorning.com/content/publishedlit/52-1034-01.pdf
34. Soto, J., Hernandez, N., Mejia, H., Grogl, M., Berman, J. (1995) Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin. Infect. Dis. 20: 47-51
35. Surber, C., Schwarb, F. P., Smith, E. W. (1999) Tape-stripping technique. In: Bronaugh, R. L., Maibach, H. I. (eds) Percutaneous absorption: drugs, cosmetics, mechanisms, methodology, 3rd edn. Dekker Inc., New York, pp 395-409
36. Sweitzer, S. M., Fann, S. A., Borg, T. K., Baynes, J. W., Yost, M. J. (2006) What is the future of diabetic wound care? Diabetes Educ. 32: 197-210
37. Vexenat, J. A., Croft, S. L., Furtado Campos, J. H., Miles, M. A. (1998) Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis. Vet. Parasitol. 77: 71-73
38. Walker, R. B., Smith, E. W. (1996) The role of percutaneous penetration enhancers. Adv. Drug Del. Rev. 18: 295-301
39. Wertz, P. W., Downing, D. T. (1987) Covalently bound omega- hydroxyacylsphingosine in the stratum corneum. Biochim. Biophys. Acta 917: 108-111
40. Williams, A. C., Barry, B. W. (2004) Penetration enhancers. Adv. Drug Del. Rev. 56: 603-618
41. Yardley, V. Croft, S. L. (2000) A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents 13: 243-248